Motley Fool Folfirinox: This potent chemotherapy mixture combines 5-FU, leucovorin, irinotecan , and oxaliplatin to treat advanced stages of pancreatic cancer. Folfirinox can be used to treat multiple types of difficult cancers, but low tolerability among patients ... and more »
DailyFinance Researchers have determined that obesity, smoking, and genetic mutations (such as testing positive for the BRCA2 gene) are three factors that can, without question, increase your risk of getting pancreatic cancer. Another factor is simply getting older ... and more »
Oncology Nurse Advisor FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan , and leucovorin) is associated with improved response rate, progression-free survival, and overall survival in persons with metastatic pancreatic cancer. However, this treatment has not been ...
PharmiWeb.com (press release) ... is well-known and has been used by the medical community for decades; however the linker has broad potential utility with proven affinity to couple with multiple chemotherapeutic agents including paclitaxel docetaxel cisplatin irinotecan and ... and more »
News-Medical.net Last September, Stivarga was approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan -based chemotherapy, an anti-VEGF therapy, and, if KRAS ... and more »
